Gene Editing, Genetic Disease, Licensing and Protein

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Editing

Genetic Disease

Licensing

Protein

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

pharmaphorum

JANUARY 10, 2022

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. CRISPR drugs can be used to modify the expression of disease-associated proteins in the body, for example, by correcting a mutation in a specific gene.

In-Vivo

In-Vivo Gene Editing Gene Therapy Gene

Advances in neuroscience drug discovery

Drug Discovery World

FEBRUARY 22, 2024

For diseases as serious and debilitating for patients and their families as leukodystrophies, learning about such advances in knowledge carries a great deal of hope, which IRCM warmly welcomes,” adds Dr Jean-François Côté, the IRCM’s President and Scientific Director.

Drugs

Drugs Gene Clinical Trials Clinical Trials

Clinical Research Informer

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Advances in neuroscience drug discovery

Stay Connected